BRIEF-Savara Announces The U.S. Food & Drug Administration (FDA) Has Extended The Review Period For The Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) In Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune Pap)

Savara, Inc.

Savara, Inc.

SVRA

0.00

April 15 (Reuters) - Savara Inc SVRA.O:

  • SAVARA ANNOUNCES THE U.S. FOOD & DRUG ADMINISTRATION (FDA) HAS EXTENDED THE REVIEW PERIOD FOR THE MOLGRAMOSTIM INHALATION SOLUTION (MOLGRAMOSTIM) BIOLOGICS LICENSE APPLICATION (BLA) IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (AUTOIMMUNE PAP)

  • SAVARA INC: PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE EXTENDED BY THREE MONTHS TO NOVEMBER 22, 2026

  • SAVARA INC - FDA EXTENDS REVIEW PERIOD FOR MOLGRAMOSTIM BLA IN AUTOIMMUNE PAP BY THREE MONTHS

Source text: ID:nBw81N4g3a

Further company coverage: SVRA.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.